Thierry Boon-Falleur

Thierry Boon-Falleur is a Professor at the Catholic University of Louvain and served as Director of the Ludwig Institute for Cancer Research (LICR) Branch in Belgium. His pioneering work established foundational principles in tumor immunology and cancer genetics, focusing on the molecular identification of tumor-specific antigens and their role in immune recognition.

His research spans cancer genetics, immunology, and molecular genetics with emphasis on T-cell recognition of tumor antigens, mechanisms of immune evasion, and antigen processing pathways. Boon-Falleur's discoveries of mutated and cancer-testis antigens (notably MAGE family genes) revolutionized understanding of tumor immunogenicity and enabled novel immunotherapeutic approaches targeting specific molecular markers.

Analysis of his publication record reveals a consistent trajectory from basic tumor immunology in the 1980s to translational cancer vaccine development by the 2000s. His work demonstrates exceptional continuity in identifying human tumor antigens recognized by cytotoxic T lymphocytes, with increasing focus on clinical applications in melanoma and other cancers. The evolution from mouse models to human therapeutic trials underscores his impact on bridging fundamental research and clinical oncology.

Honors and awards include:

• Prix Rik et Nel Wouters pour la recherche sur le cancer (1986)
• Prix De Vooght d'Immunologie (1986)
• Cancer Research Institute Award for Research in Immunology (1987)
• Dr Joseph Steiner Cancer prize (1990)
• Prix Francqui (1990)
• Prix Louis Jeantet (1994)
• Rabbi Shai Shacknai Memorial Prize (1994)
• Prix Sandoz d'Immunologie (1995)
• Prix Léopold Griffuel (1999)

As LICR Director, Boon-Falleur led multinational research teams that established critical methodologies for antigen discovery and validation. His laboratory pioneered the identification of human tumor rejection antigens through T-cell cloning techniques, creating the conceptual framework for modern cancer immunotherapy. Current research directions likely focus on overcoming tumor immune evasion mechanisms identified in his earlier work on HLA loss and antigen processing defects.